Form 4: Incyte Executive Granted Performance Shares Tied to Total Shareholder Return

Incyte Corp's EVP, Head of Tech. Operations, Michael James Morrissey, was granted 10,961 performance shares, which can yield up to 200% of common stock based on the company's relative total shareholder return over a three-year period.

Summary

• Michael James Morrissey, Executive Vice President and Head of Technical Operations at Incyte Corp (INCY), was granted 10,961 performance shares.
• The grant date for these performance shares was July 15, 2025.
• Each performance share represents the right to receive up to 200% of one share of Incyte's common stock.
• The actual number of shares earned will be determined by Incyte's relative Total Shareholder Return (TSR) compared to a fixed peer group over a three-year performance period.
• This performance period commenced on January 1, 2025.
• Earned shares are scheduled to vest on July 15, 2028, contingent upon Mr. Morrissey's continued service with the company.

Sentiment

Score: 7

Explanation: The grant of performance shares to a key executive is a positive sign of long-term incentive alignment, though the actual value is contingent on future performance and continued service.

Positives

• The grant of performance shares aligns the executive's long-term incentives directly with shareholder returns, promoting a focus on company performance.
• The structure of the award, tied to relative Total Shareholder Return, encourages competitive performance against industry peers.

Risks

• The actual value of the performance shares is contingent on Incyte's future Total Shareholder Return performance relative to its peer group, meaning the full potential value may not be realized.
• The vesting of earned shares is subject to the reporting person's continued service with the issuer, posing a risk if employment ceases before the vesting date.

Future Outlook

The future outlook for the granted performance shares is directly tied to Incyte's Total Shareholder Return performance over the three-year period ending January 1, 2028, with the potential for the executive to receive up to 200% of the granted shares based on this performance.

Management Comments

• Each performance share represents the right to receive up to 200% of one share of common stock.
• Such shares may be earned based upon the issuer's relative total shareholder return ('TSR') over a three-year performance period beginning on January 1, 2025, as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement.
• The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.

Industry Context

Performance share grants tied to relative Total Shareholder Return are a common and widely accepted executive compensation practice across the biopharmaceutical industry and broader corporate sectors. This approach aims to align executive incentives with long-term shareholder value creation and competitive performance within a defined peer group.

Comparison to Industry Standards

• This type of performance-based equity award is a standard component of executive compensation packages in the pharmaceutical and biotechnology sectors.
• Similar compensation structures, where long-term incentives are tied to relative shareholder performance or specific operational milestones, are observed at comparable companies such as Pfizer, Merck, and Amgen, reflecting a common industry approach to executive motivation and retention.

Related Party Transactions

• Grant of 10,961 performance shares to Michael James Morrissey, EVP, Head of Tech. Operations, as part of his executive compensation package.

Stakeholder Impact

• Shareholders: The performance-based nature of the grant aims to align the executive's interests with long-term shareholder value creation, potentially benefiting shareholders if the company's TSR performs well.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The three-year performance period for the performance shares will continue until January 1, 2028.
• The earned shares are scheduled to vest on July 15, 2028, subject to the executive's continued employment.

Key Dates

Keywords

Incyte Corp, INCY, SEC Form 4, Performance Shares, Executive Compensation, Stock Grant, Total Shareholder Return, TSR, Insider Transaction